3+ day, 5+ hour ago   (320+ words) AllSci San Francisco-based Chai Discovery and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to apply Chai's generative AI antibody discovery platform across BMS's broader portfolio, with the stated goal of building an AI-powered, continuously learning discovery system at…...

3+ day, 5+ hour ago   (86+ words) AI-guided AAV engineering has become an increasingly competitive field. Dyno Therapeutics has established capsid discovery collaborations with Roche and Astellas, with Astellas exercising a license option in April 2026 for an AI-designed skeletal muscle-targeting capsid. Other developers have similarly focused on…...

3+ day, 5+ hour ago   (53+ words) Category: Clinical Trial Reform | Regulatory Body: FDA (CBER, CDER, CDRH, OCE) | Geography: United States | Instrument: Guidance document Access the AllSci platform to explore the science behind the news. Have a question or correction on this story? Contact [email protected]. Learn…...

4+ day, 3+ hour ago   (132+ words) A prospective, blinded competition involving 29 organizations and 511 AI-designed antibody sequences has producedone of the largest prospective, blinded benchmarks of computational antibody design to date — and found that performance varies so widely across groups and tasks that no single algorithmic approach…...

5+ day, 5+ hour ago   (137+ words) Palo Alto-based Network Bio has launched with USD 50 million in financing to build disease-specific AI models trained on multimodal patient tissue, blood, and longitudinal clinical data — a platform the company said is already generating transferable disease signals across conditions it…...

5+ day, 12+ hour ago   (81+ words) The paper also addresses two technically complex areas: foundation models, which may underpin multiple downstream applications, and agentic AI systems capable of autonomous decision-making with limited human oversight. For each domain, the FDA poses targeted questions to guide stakeholder input…...

1+ week, 5+ day ago   (326+ words) AllSci Israel-based Nucleai announced an ongoing translational research collaboration with Gilead Sciences supporting Gilead's global antibody-drug conjugate (ADC) clinical development programs, applying Nucleai's AI-powered Tissue Intelligence platform to generate spatial biomarkers and translational insights across multiple oncology indications. Under the…...

1+ week, 6+ day ago   (157+ words) Artificial Axon Labs Inc., a Massachusetts-based MIT spinout, has received a USD 1.48 million SBIR R44 Phase II renewal from the National Institute of Neurological Disorders and Stroke (NINDS) to advance a 3D-printed biomimetic drug screening platform aimed at identifying remyelinating therapies…...

2+ week, 4+ hour ago   (427+ words) AllSci Barcelona-based Almirall, S.A. (ALM) and China-based Shenzhen CrystalO Biopharma Technology Co., Ltd. announced a collaboration and licensing agreement to discover and develop novel small-molecule ion channel modulators for skin diseases. The deal gives Almirall exclusive rights to develop, manufacture, and…...

2+ week, 4+ hour ago   (123+ words) Novo Nordisk (Copenhagen: NOVO B) and Amazon Web Services (AWS) announced a strategic partnership that establishes AWS as Novo Nordisk's preferred cloud provider and names the two companies as co-founders of a joint AI innovation hub in London, where engineers and…...